Sanofi, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. Its principle pharmaceutical products include Lantus and Apidra analogs of human insulin; Insuman range of human insulin solutions and suspensions; Amaryl, an oral once-daily sulfonylurea; BGStar and iBGStar blood glucose meters; enzyme replacement therapies, such as Cerezyme to treat Gaucher disease, Fabrazyme to treat Fabry disease, and Myozyme/Lumizyme to treat Pompe disease; Taxotere, a taxane derivative for various cancer types; Eloxatine treating colorectal cancer; and Jevtana for patients with prostate cancer. The companyĺs other flagship products comprise thrombosis medicines, including Plavix anti-platelet agent indicated for atherothrombotic conditions and Lovenox for the prevention and treatment of deep vein thrombosis and for unstable angina and myocardial infarction; cardiovascular medicines consisting of Multaq, an anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments; Renagel/Renvela oral phosphate binders used in patients with chronic kidney disease on dialysis to treat high phosphorus levels; and Synvisc and Synvisc-One viscosupplements used to treat pain associated with osteoarthritis of certain joints. It also offers pediatric combination, influenza, adult and adolescent booster, meningitis, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and other prescription drugs, including generics. It has alliance arrangements with Bristol-Myers Squibb and Warner Chilcott. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.